1. Combinatorial Epigenetic and Immunotherapy in Breast Cancer Management: A Literature Review
- Author
-
Yu-Ting Lee, Yu-Ming Chuang, and Michael W.Y. Chan
- Subjects
0301 basic medicine ,Oncology ,medicine.medical_specialty ,Combination therapy ,Health, Toxicology and Mutagenesis ,medicine.medical_treatment ,lcsh:Medicine ,Review ,Biochemistry, Genetics and Molecular Biology (miscellaneous) ,Biochemistry ,combination therapy ,immune checkpoint inhibitors ,03 medical and health sciences ,0302 clinical medicine ,Breast cancer ,breast cancer ,Internal medicine ,Genetics ,Medicine ,lcsh:QH301-705.5 ,Tumor microenvironment ,business.industry ,lcsh:R ,Cancer ,Immunotherapy ,medicine.disease ,Immune checkpoint ,epi-drug ,Clinical trial ,030104 developmental biology ,Immunoediting ,lcsh:Biology (General) ,030220 oncology & carcinogenesis ,business - Abstract
Breast cancer is one of the leading causes of death among cancer patients worldwide. To date, there are several drugs that have been developed for breast cancer therapy. In the 21st century, immunotherapy is considered a pioneering method for improving the management of malignancies; however, breast cancer is an exception. According to the immunoediting model, many immunosuppressive cells contribute to immunological quiescence. Therefore, there is an urgent need to enhance the therapeutic efficacy of breast cancer treatments. In the last few years, numerous combinatorial therapies involving immune checkpoint blockade have been demonstrated that effectively improve clinical outcomes in breast cancer and combining these with methods of targeting epigenetic regulators is also an innovative strategy. Nevertheless, few studies have discussed the benefits of epi-drugs in non-cancerous cells. In this review, we give a brief overview of ongoing clinical trials involving combinatorial immunotherapy with epi-drugs in breast cancer and discuss the role of epi-drugs in the tumor microenvironment, including the results of recent research.
- Published
- 2020